JP2024528705A5 - - Google Patents
Info
- Publication number
- JP2024528705A5 JP2024528705A5 JP2024503903A JP2024503903A JP2024528705A5 JP 2024528705 A5 JP2024528705 A5 JP 2024528705A5 JP 2024503903 A JP2024503903 A JP 2024503903A JP 2024503903 A JP2024503903 A JP 2024503903A JP 2024528705 A5 JP2024528705 A5 JP 2024528705A5
- Authority
- JP
- Japan
- Prior art keywords
- present
- gpa
- acid
- cancer
- cancer cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163223926P | 2021-07-20 | 2021-07-20 | |
| US63/223,926 | 2021-07-20 | ||
| PCT/US2022/073884 WO2023004308A1 (en) | 2021-07-20 | 2022-07-19 | Compositions and methods for inhibiting creatine transport as a treatment for cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024528705A JP2024528705A (ja) | 2024-07-30 |
| JP2024528705A5 true JP2024528705A5 (enExample) | 2025-07-25 |
Family
ID=84979767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503903A Pending JP2024528705A (ja) | 2021-07-20 | 2022-07-19 | がんのための治療としてのクレアチン輸送を阻害するための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240180912A1 (enExample) |
| EP (1) | EP4373582A4 (enExample) |
| JP (1) | JP2024528705A (enExample) |
| AU (1) | AU2022316200A1 (enExample) |
| CA (1) | CA3225305A1 (enExample) |
| WO (1) | WO2023004308A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4596552A1 (en) | 2022-09-29 | 2025-08-06 | Guangzhou Joyo Pharmatech Co., Ltd | Macrocyclic derivative and use thereof |
| CN116602948B (zh) * | 2023-06-06 | 2024-12-06 | 湖南岳靶生物医药有限公司 | 一种可用于降低膀胱癌细胞耐药性的化合物、组合物及其应用 |
| WO2025114580A1 (en) * | 2023-11-30 | 2025-06-05 | National And Kapodistrian University Of Athens | N-aminoguanidine derivatives with anticancer activity |
| CN121873253A (zh) * | 2026-01-20 | 2026-04-17 | 合肥综合性国家科学中心大健康研究院 | 抗slc6a8的抗体或其抗原结合片段及其组合物和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2914344B1 (en) * | 2012-10-31 | 2020-01-15 | The Rockefeller University | Treatment of metastatic colon cancer |
| US20180002702A1 (en) * | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| WO2016176636A1 (en) * | 2015-04-30 | 2016-11-03 | Rgenix, Inc. | Inhibitors of creatine transport and uses thereof |
| EP4034084B1 (en) * | 2019-09-27 | 2025-11-05 | The Rockefeller University | Compositions and methods for treating metastatic gastrointestinal cancer |
| GEP20247638B (en) * | 2019-10-22 | 2024-07-10 | Lupin Ltd | Pharmaceutical combination of prmt5 inhibitors |
| JP2023505687A (ja) * | 2019-12-11 | 2023-02-10 | インスピルナ，インコーポレーテッド | 癌の処置方法 |
-
2022
- 2022-07-19 EP EP22846790.8A patent/EP4373582A4/en active Pending
- 2022-07-19 WO PCT/US2022/073884 patent/WO2023004308A1/en not_active Ceased
- 2022-07-19 AU AU2022316200A patent/AU2022316200A1/en active Pending
- 2022-07-19 JP JP2024503903A patent/JP2024528705A/ja active Pending
- 2022-07-19 CA CA3225305A patent/CA3225305A1/en active Pending
-
2024
- 2024-01-19 US US18/417,491 patent/US20240180912A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yamada et al. | S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial | |
| EP4337191A1 (en) | Egfr inhibitor for the treatment of head and neck cancer | |
| LoConte et al. | A multicenter phase 1 study of γ-secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors | |
| US20110053879A1 (en) | Picoplatin and amrubicin to treat lung cancer | |
| Bajetta et al. | Phase II study of pemetrexed disodium (Alimta®) administered with oral folic acid in patients with advanced gastric cancer | |
| JP2019532051A5 (enExample) | ||
| US12102613B2 (en) | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms | |
| JP2023523323A5 (enExample) | ||
| CN113750238A (zh) | 包含瓦尼替尼及抗癌剂之组合疗法 | |
| JP2024527109A5 (enExample) | ||
| CN110198716A (zh) | 癌症治疗 | |
| CN118201616A (zh) | 用于癌症的wee1抑制剂 | |
| TWI869511B (zh) | 治療癌症之方法 | |
| WO2021018310A1 (zh) | 用于治疗非小细胞肺癌的氨基吡啶衍生物 | |
| CN115006397A (zh) | 一种预防或治疗肿瘤疾病的药物用途 | |
| US20190105323A1 (en) | Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake | |
| WO2011092338A1 (en) | Combined treatment of pancreatic cancer with gemcitabine and masitinib | |
| Planchard et al. | A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS-or BRAF-mutant non-small cell lung cancer | |
| JP2005513167A (ja) | エポシロン誘導体と代謝拮抗剤からなる組合せ | |
| CN102883720A (zh) | 治疗胰腺癌的方法 | |
| TW201628608A (zh) | 治療或緩解高齡或末期癌症患者用之醫藥組合物 | |
| Sawicka et al. | Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question? | |
| CN111867591A (zh) | 治疗胆道癌的方法和组合疗法 | |
| Takiguchi et al. | Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study | |
| CN115135326A (zh) | 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途 |